TAPI (Arriva)

The intended divestiture is expected to play an important role in Teva's “Pivot to Growth” strategy as it will allow Teva to focus on its core business strengths and on capital allocation towards growth engines and innovation Such intended divestiture of Teva’s API business is expected to enhance TAPI's position as a global leader in the growing API market TEL AVIV, Israel--(BUSINESS WIRE)-- Teva announced today its intention to divest its active-pharmaceutical ingredient (API) business, or "TAPI". TAPI is a global leader in the small-molecule API industry, with approximately 4,300 employees worldwide. The intent to divest “TAPI” will allow Teva to maximize current and potential revenue streams, focusing on capital reallocation towards growth and innovation, and to better serve patients. The intended divestiture is expected to create additional value for Teva’s shareholders and other stakeholders by allowing Teva to better address distinct, growing markets with Teva’s leading product offerings. It will also allow the divested company to pursue new growth strategies, enabling it to maximize an array of opportunities in the $85 billion global API market. Richard Francis, Teva's President and CEO said: "The divestiture of TAPI will play an important role in the execution of our Pivot to Growth strategy in this new era for Teva, as it will allow us to increase the focus on our core business, continue to invest in our growth drivers, accelerate our innovative and biosimilar pipeline, and position our generics portfolio and pipeline to drive growth for the future." R. Ananth, CEO of TAPI said: "Our goal, operating outside of Teva, is to enable TAPI to maximize its potential for growth, capture more opportunities with third-party customers, leverage its technology, expand its capabilities and continue to support generics players and innovators, including Teva, worldwide." Teva expects the intended divestiture to be completed in the first half of 2025, subject to reaching a satisfactory agreement on transaction terms with a prospective purchaser, the successful satisfaction of closing conditions, and the approval of an agreed transaction by Teva’s Board of Directors. However, there can be no assurance regarding the ultimate timing or structure of the potential divestiture or that a divestiture will be agreed or completed at all. About TAPI TAPI is a world-leading provider of small molecule active pharmaceutical ingredients (API). With extensive expertise in the development and manufacturing of high-quality API products, TAPI serves more than 1,000 clients globally, including Biotechnology & Pharmaceutical companies. TAPI’s robust portfolio of 350 products serve a diverse range of both generic and innovative therapeutic areas. TAPI’s operations are integral to the delivery of high-quality, safe and effective medications to patients worldwide, supported by a sophisticated supply chain, focused innovative manufacturing, regulatory and quality excellence and a commitment to sustainability. https://www.teva-api.com . About Teva Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a global pharmaceutical leader with a category-defying portfolio, harnessing our generics expertise and stepping up innovation to continue the momentum behind the discovery, delivery, and expanded development of modern medicine. For over 120 years, Teva's commitment to bettering health has never wavered. Today, the company’s global network of capabilities enables its ~37,000 employees across 58 markets to push the boundaries of scientific innovation and deliver quality medicines to help improve health outcomes of millions of patients every day. To learn more about how Teva is all in for better health, visit www.tevapharm.com . Cautionary Note Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. All statements other than statements of historical fact are, or may be deemed to be, forward-looking statements. In some cases, you can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks and uncertainties relating to: our ability to successfully turn our Teva API business into a stand-alone “TAPI” unit and leader in the API market; our ability to divest TAPI; the terms, timing, structure, benefits and costs of any divestiture transaction and whether one will be consummated at all; the impact of any divestiture transaction on the remaining businesses of Teva; our ability to satisfy the conditions to completing the divestiture of TAPI; our ability to successfully execute on our Pivot to Growth strategy including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development, and to sustain and focus our portfolio of generics medicines; the impact of the potential TAPI divestiture on our ability to attract, hire, integrate and retain highly skilled personnel; and other factors discussed in our Annual Report on Form 10-K for the year ended December 31, 2022 and once filed, our Annual Report on Form 10-K for the year ended December 31, 2023, including in the sections captioned "Risk Factors” and “Forward Looking Statements.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements. View source version on businesswire.com : https://www.businesswire.com/news/home/20240131314557/en/ IR Contacts Ran Meir (215) 591-8912 Yael Ashman +972 (3) 914 8262 Sanjeev Sharma (267) 658-2700 PR Contacts Kelley Dougherty (973) 832-2810 Eden Klein +972 (3) 906 2645 Source: Teva Pharmaceutical Industries Limited